On July 27 2010, Cytori surprised its investors by announcing that approval was received (together with breast augmentation and re-construction) for: The delivery of the Celution(R) System cellular output to facilitate healing of rectal and vaginal fistulas (wounds) resulting from Crohn's disease, the first stem cell-based approval in Europe for this condition.
Up to that day, a coincidental statement by Chris Calhoun, CEO on the treatment of some patients with this disorder, was subsequently corrected by the legal department "as a slip of the tongue". This article will try to shed some light on this "mystery" approval and will explain the aspects of the condition.

Copyright Information

Copyright Fas Kuiters © 2019-2020 raccoon-lodge.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.